Variation Biotechnologies, Inc. to Present at the 22nd Annual Piper Jaffray Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Variation Biotechnologies, Inc. today announced that it is scheduled to present at the 22nd Annual Piper Jaffray Health Care Conference being held at the New York Palace in New York City. Jeff Baxter, chief executive officer at Variation, will provide an overview of the Company and its progress in key vaccine formulation and delivery programs on Tuesday, November 30, 2010 at 8:50 a.m. ET.

About Variation Biotechnologies, Inc.

VBI is an emerging leader in the innovative formulation, delivery and development of vaccines. The Company’s powerful, proprietary technology platforms enable thermostable IM and thermostable oral vaccine delivery, creating improved dose equivalent and the potential for dose sparing and adjuvanted vaccines, extending vaccine reach and coverage in established and emerging markets. VBI’s innovative approach to vaccine development and its growing pipeline of vaccine programs address significant market opportunity and are designed to answer critical unmet medical need. For more information, please visit www.variationbiotech.com.



CONTACT:

Variation Biotechnologies, Inc.
Dan Budwick, 973-271-6085, [email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Pharmaceutical

MEDIA:

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.